APOB and metabolic syndrome: Similarly, the 2021 ESC Guidelines on CVD prevention state that, in high-risk (or higher) patients with fasting TG ≥ 1.5 mmol/L (135 mg/dL) despite statins and lifestyle, icosapent ethyl 2 g twice daily may be considered, while the 2019 ESC/EAS dyslipidemia management guidelines emphasize measurement of non–HDL-C and apoB after LDL-C and advocate the selective use of TG-lowering strategies—including icosapent ethyl—for patients with mixed dyslipidemia or high risk patients [66–69, 72].